Document is current

Article History

Accepted: 4 July 2025

First Online: 1 August 2025

Declarations

:

: This study was sponsored by BridgeBio Pharma, Inc., San Francisco, CA, USA.

: N.D. is a consultant and advisor for Alexion and AstraZeneca; and a speaker for Alnylam. S.H.P. is a consultant and has received fees from BridgeBio, Pfizer, and AstraZeneca; and research support from Novo Nordisk. M.E. and A.V.A. have no relevant financial relationships to disclose. K.B.S. is a consultant, advisor, and speaker for Pfizer. L.H., S.S., J.F.T., and H.F. are employees and stakeholders of BridgeBio Pharma, Inc., San Francisco, CA, USA. R.M., M.A., and P.S. are employees of Definitive Healthcare. J.L.G. is a researcher for Texas Health Resources Clinical Scholarship, Eidos/BridgeBio, Pfizer, and NHLBI R01HL160892; and a consultant and advisor for Pfizer, Eidos/BridgeBio, AstraZeneca, Intellia, Tenax Therapeutics, Alnylam, Novo Nordisk, Lumanity, Ultromics, and Alexion.

: Qualified academic investigators may submit requests for access to aggregated/summary data that support the findings of this study via MedInfo@BridgeBio.com. Requests for access to study data will be evaluated by BridgeBio Pharma, Inc., and access will be provided contingent upon the approval of a research/study proposal and the execution of a data sharing agreement. BridgeBio Pharma will consider requests for access to participant-level data if participant privacy is assured through methods such as data deidentification, pseudonymization, or anonymization (as required by applicable law), and if such disclosures were included in the relevant study’s informed consent form or study protocol.

: The ATTRibute-CM (NCT03860935) trial was conducted in accordance with the International Council for Harmonization, Good Clinical Practice, and the Declaration of Helsinki. The trial was approved by an ethics committee at each participating site.

: All participants provided written informed consent to participate in the ATTRibute-CM study.

: Not applicable.

: N.D. contributed to investigation, writing—original draft, and writing—review and editing. S.H.P. contributed to writing—original draft and writing—review and editing. M.E. contributed to writing—original draft and writing—review and editing. A.V.A. contributed to investigation, writing—original draft, and writing—review and editing. K.B.S. contributed to writing—original draft and writing—review and editing. L.H. and H.F. contributed to the methodology, writing—original draft, and writing—review and editing. S.S. contributed to investigation, writing—original draft, and writing—review and editing. J.F.T. contributed to investigation, writing—original draft, and writing—review and editing. R.M. contributed to writing—original draft and writing—review and editing. M.A. contributed to investigation, writing—original draft, and writing—review and editing. P.S. contributed to writing—original draft and writing—review and editing. J.L.G. contributed to investigation, writing—original draft, and writing—review and editing.